First FDA-approved PROTAC: Vepdegestrant moves targeted protein degradation into oncology practice

The Innovation Drug Discovery 2026 Open access

Read full text

Authors: Zhuang Hu, Zuxian Xu, Xin Peng

DOI: 10.59717/j.xinn-drugdisc.2026.100020

Cited by: 1

References: 3

Fields of Study & Subjects

Protein Degradation and Inhibitors Histone Deacetylase Inhibitors Research Peptidase Inhibition and Analysis

References 3